Serum CD40/CD40L system in Graves' disease and Hashimoto's thyroiditis related to soluble Fas, FasL and humoral markers of autoimmune response.
Activated CD4 T cells' express CD40 ligand (CD154) interacting with CD40 on the B cells surface, protecting them from Fas-mediated apoptosis and in this study, influence humoral response. The aim of the study was to assess soluble CD40 and CD154 in Graves' disease (GD) and Hashimoto's thyroiditis (HT) in relation to Fas and FasL and to the markers of humoral response: aTPO, aTG and aTSHR. The study was carried out in 5 groups of subjects: 1/14 patients with GD in euthyreosis on methimazol (euGD), 2/20 patients with hyperthyroid GD (hrGD), 3/15 patients with HT in euthyreosis on levothyroxine (euHT), 4/16 patients with hypothyroid Ht (hoHT), 5/12 healthy volunteers, age and sex-matched to groups 1-4. The serum levels of CD40, CD154, Fas and FasL, aTPO and aTG were determined by ELISA and aTSHR was determined by the RIA method. CD40 serum concentration was significantly higher in hoHT individuals: 55.8 (24.0-83.2) pg/ml (p<0.01) and euHT patients: 51.2 (20.0-80.1) (p<0.05) as compared to the controls. Also sCD40L values were significantly increased in euHT individuals: 5.1 (1.0-11.8) (p<0.05) and hoHT patients: 3.9 (0.7-11.2) ng/ml (p<0.05) as compared to the controls. There was a positive correlation between sCD40 and sCD154 in the patients studied (r=0.36, p<0.001). In HT patients we found positive correlations between sCD40 and aTPO (r=0.45, p<0.001) and sFas (r=0.36, p<0.05) as well as a negative correlation between sCD40 and FasL (r=-0.24, p<0.05). In GD patients there was a positive correlation between sCD40 and aTSHR (r=0.28, p<0.05). In summary, our results suggest that CD40/CD154 interaction plays an important role in the regulation of autoimmune humoral response, both in Hashimoto's thyroiditis and Graves' disease. Fas-mediated apoptosis seems to be involved in this process especially in Hashimoto thyroiditis. Soluble CD40 may serve as a marker of the active stage of autoimmune thyroid disease.
Mysliwiec
Janusz
J
Department of Endocrinology, Diabetology and Internal Diseases, Medical University of Bialystok, Poland. mysjan@poczta.onet.pl
Oklota
Magdalena
M
Nikolajuk
Agnieszka
A
Waligorski
Dariusz
D
Gorska
Maria
M
D000328:Adult; D000917:Antibody Formation; D015551:Autoimmunity; D015415:Biomarkers / Q000097:blood*; D019013:CD40 Antigens / Q000097:blood*; D023201:CD40 Ligand / Q000097:blood*; D053222:Fas Ligand Protein; D005260:Female; D006111:Graves Disease / Q000097:blood / Q000276:immunology*; D050031:Hashimoto Disease / Q000097:blood / Q000276:immunology*; D006801:Humans; D008297:Male; D008875:Middle Aged
D015415:Biomarkers; D019013:CD40 Antigens; D053222:Fas Ligand Protein; D023201:CD40 Ligand